Your company’s employer brand is your reputation as an employer and is crucial in attracting top talent. Some reputations are just not good; they may or not be deserved. That is just the perception in the market. Years ago there…
HOME > TOP STORIES
TOP STORIES
-
REGULATORY LDP’s Hashimoto Makes Rare Speech on Drug Prices amid Close Race in Okayama
October 22, 2024
-
BUSINESS Pfizer Veteran Pullicino to Lead Novartis Japan
October 22, 2024
-
BUSINESS Ferring Japan Set for 15% Annual Growth as It Gazes at Gene Therapy Debut
October 21, 2024
-
BUSINESS Moderna CEO Maintains Future Vision for Product Mix despite R&D Cutback, Eyes Leap with Flu-COVID Shot
October 18, 2024
-
BUSINESS Ultragenyx Looks to Launch 6 New Products in Japan by 2028-End: CCO
October 17, 2024
-
REGULATORY Multiple Candidates Tout Drug Policies as Snap Poll Campaigning Starts
October 16, 2024
-
BUSINESS Shonan iPark Set for Expansion as It Looks to Establish Profile as Regenerative Medicine Hub
October 16, 2024
-
REGULATORY Japan Political Parties Push Varied Pharma Policies as Election Campaign Kicks Off
October 15, 2024
-
ORGANIZATION EFPIA Chief Sees Positive Signal from Japan Policymakers, Calls for Consistency
October 11, 2024
-
REGULATORY Kisunla to Follow Same Rules as Leqembi in Pricing and Post-Launch Review
October 10, 2024
-
BUSINESS Pfizer Curbs Supply of Avastin Biosimilar, 2 Others Hit by Knock-On Effect
October 9, 2024
-
BUSINESS Supply Curb Hits New Generic of Hirudoid Lotion, Demand Driven by Elective Care?
October 8, 2024
-
BUSINESS J&J Eyes Double-Digit Growth in Japan Pharma Biz from 2027, 50 Approvals by 2029
October 7, 2024
-
REGULATORY Panel OKs Withdrawal Rule for Conditional Nod, 2-Year Extension for Pediatric Data Protection towards PMD Act Amendment
October 4, 2024
-
ORGANIZATION Policy Veterans’ Group Proposes Special Drug Price Rule for Antibiotics
October 3, 2024
-
REGULATORY New Health Minister Eager to Build Pharma Ecosystem in Japan
October 3, 2024
-
REGULATORY New Finance Minister Vows Full Discussions with MHLW on FY2025 Revision
October 3, 2024
-
REGULATORY New Cabinet Might Move the Needle in Off-Year Debate: Industry Exec
October 2, 2024
-
REGULATORY Japan’s New PM Eyes Social Security Reform as Cabinet Unveiled
October 2, 2024
-
REGULATORY Takamaro Fukuoka Named as New Health Minister
October 1, 2024
ページ
The global race to develop so-called “double G” and “triple G” agonists is heating up to boost the efficacy of…
A Japanese health ministry panel on December 26 wrapped up its discussions on the next amendment of the Pharmaceuticals and…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…